Zimmer Biomet (ZBH) acquired CD Diagnostics, developer of immunoassays and biomarker testing to inform treatment decisions. Financial terms were not disclosed.
The companies initially partnered in 2012 to co-develop diagnostics for musculoskeletal applications, which led to marketing of the Synovasure® diagnostic test for periprosthetic joint infection. Synovasure received EU regulatory clearance in 4Q14.
CD Diagnostics can analyze synovial fluid to investigate biomarker profiles for various clinical conditions, and create diagnostic assays that inform patient care decisions. Synovasure is reportedly able to yield information on joint infection within hours of testing.
The acquisition complements ZBH’s U.S. offering, Signature Solutions™, a suite of clinical services and technologies to support hospitals and medical practices in the transition to value-based healthcare models.
Zimmer Biomet (ZBH) acquired CD Diagnostics, developer of immunoassays and biomarker testing to inform treatment decisions. Financial terms were not disclosed.
The companies initially partnered in 2012 to co-develop diagnostics for musculoskeletal applications, which led to marketing of the Synovasure® diagnostic test for...
Zimmer Biomet (ZBH) acquired CD Diagnostics, developer of immunoassays and biomarker testing to inform treatment decisions. Financial terms were not disclosed.
The companies initially partnered in 2012 to co-develop diagnostics for musculoskeletal applications, which led to marketing of the Synovasure® diagnostic test for periprosthetic joint infection. Synovasure received EU regulatory clearance in 4Q14.
CD Diagnostics can analyze synovial fluid to investigate biomarker profiles for various clinical conditions, and create diagnostic assays that inform patient care decisions. Synovasure is reportedly able to yield information on joint infection within hours of testing.
The acquisition complements ZBH’s U.S. offering, Signature Solutions™, a suite of clinical services and technologies to support hospitals and medical practices in the transition to value-based healthcare models.
Copy to clipboard 
